The nation’s leading doctors groups are in a standoff with federal health officials over vaccines. The conflict intensified ...

Merck’s MRK stock has been trading above its 50-day and 200-day simple moving averages (SMAs) since early November, ...

Two new Cochrane reviews by UK researchers provide strong, consistent evidence that human papillomavirus (HPV) vaccination ...

Hundreds of studies, including gold-standard clinical trials, challenge Health Secretary Robert F. Kennedy Jr.’s claim that ...

Merck MRK is facing persistent challenges for its second-largest product, Gardasil, which is a vaccine for the prevention of certain cancers caused by human papillomavirus. Though the vaccine’s sales ...

Merck’s MRK second-largest product Gardasil is a vaccine for the prevention of certain cancers caused by human papillomavirus (HPV). Though the vaccine’s sales were consistently rising till 2022, it ...

Pharmaceutical giants are navigating a complex landscape of fluctuating demand and regulatory hurdles, impacting their financial performance and strategic outlook. Merck & Co. Inc. (NYSE:MRK) is the ...

However, excluding GARDASIL China, sales would have grown 7%, highlighting the significant impact of this single product in a specific market. As shown in the following quarterly performance summary: ...

Despite indications that a single dose of Merck's (NYSE:MRK) human papillomavirus vaccine Gardasil could be as effective as the current multi-dosing schedule, the drugmaker said that an alternative ...

A federal judge ruled in Merck & Co.’s favor in a safety lawsuit over its Gardasil vaccine, allowing the drugmaker to sidestep more than 200 cases claiming the company concealed safety risks. The ...

A federal judge ruled in favor of Merck in litigation accusing it of concealing the risks of Gardasil, a vaccine to prevent cervical and other cancers caused by the human papillomavirus and one of the ...